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Summary. The macrolide, FK-506, is a potent and effec- 
tive inhibitor of lymphocyte activation. We studied the 
effects of FK-506 on human neutrophil activation in- 
duced by chemoattractants and by various substances 
which circumvent receptor stimulation. After preincuba- 
tion for 5 min at 37 °C, FK-506 (1 gM) inhibited N-for- 
myl-L-methionyl-L-leucyl-L-phenylalanine (fMet-Leu- 
Phe)- or platelet-activating factor-induced superoxide 
production in neutrophils by about 30°7o. At therapeutic 
concentrations (0.1-1nM) FK-506 was ineffective. 
FK-506 did not inhibit exocytosis and rises in cytosolic 
Ca 2÷ concentration [Ca2+] i mediated by these stimuli, 
and it did not at all inhibit neutrophil activation induced 
by C5a, leukotriene B 4 and 4fl-phorbol 12-myristate 
13-acetate. FK-506 (1 gM) inhibited A23187-induced ex- 
ocytosis by about 35%, but A23187-induced superoxide 
production was unaffected. After preincubation for 
5 min at 37 °C, FK-506 inhibited fMet-Leu-Phe-induced 
superoxide production in dibutyryl cAMP-differentiated 
HL-60 cells by about 20%; preincubation with the drug 
for 24 h did not result in inhibition of superoxide produc- 
tion. FK-506 did not inhibit agonist-binding to formyl 
peptide receptors and fMet-Leu-Phe-stimulated GTP hy- 
drolysis of heterotrimeric regulatory guanine nucleotide- 
binding proteins (G-proteins) in membranes from dibuty- 
ryl cAMP-differentiated HL-60 cells. FK-506 did not 
change steady-state and differential polarized phase fluo- 
rescence in Hb60 membranes using 1,6-diphenylhexa- 
1,3,5-triene and 12-(9-anthroyloxy)-stearate as probes. 
Our results how that FK-506 at supratherapeutic concen- 
trations partially inhibits neutrophil activation. Inhibi- 
tion by FK-506 of fMet-Leu-Phe-induced superoxide pro- 
duction is rapid in onset and is not due to inhibition of 
agonist-binding toreceptors, interference with G-proteins 
or protein kinase C, reduction of rises in [Ca2+]i or al- 
teration in physical membrane state. 
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Introduction 
Human neutrophils play an important role in non-specif- 
ic host defense against bacterial infections (Malech and 
Gallin 1987). In neutrophils and differentiated HL-60 
cells, receptors for platelet activating factor (PAF), com- 
plement C5a, leukotriene B4 and N-formyl-L-methionyl- 
L-leucyl-L-phenylalanine (fMet-Leu-Phe), couple to het- 
erotrimeric regulatory guanine nucleotide-binding pro- 
teins (G-proteins) (Rossi 1986; Sandborg and Smolen 
1988; Dillon et al. 1988; Seifert and Schultz 1991). Acti- 
vation of G-proteins results in phosphoinositide grada- 
tion with subsequent activation of protein kinase C, in- 
crease in cytosolic Ca 2+ concentration [Ca2+]i , activa- 
tion of superoxide (02) production and exocytosis (Ros- 
si 1986; Sandborg and Smolen 1988; Dillon et al. 1988; 
Seifert and Schultz 1991). 
FK-506 is an immunosuppressant macrolide from 
Streptomyces tsukabaensis (Kino et al. 1987). The in vivo 
and in vitro effects of FK-506 and cyclosporin A (CsA) 
are similar, although there are substantial differences in 
potency and chemical structure of the immunosup- 
pressants (Sigal and Dumont 1992). Similar to CsA, 
FK-506 inhibits mitogenic or antigenic stimulation of T- 
and B-lymphocytes at early stages (Wicker et al. 1990; 
Chang et al. 1991; Sigal and Dumont 1992). In addition, 
FK-506 and CsA interfere with signal transduction 
pathways associated with rises in [Ca2+]i (Lin et al. 
1991). However, inhibition by FK-506 and CsA of in- 
terleukin-2 synthesis i not associated with a reduction in 
[Ca2+] i (Metcalfe 1984; Ryffel 1989; Bierer et al. 1990). 
The intracellular binding proteins for CsA and FK-506, 
cyclophilin and FK-506-binding protein (FKBP), respec- 
tively, do not share amino acid sequence homology 
(Siekierka et al. 1989; Harding et al. 1989), but both im- 
munosuppressant-immunophilin-complexes inhibit the 
CaZ+-/calmodulin-dependent phophatase, calcineurin 
(Liu et al. 1991). 
At therapeutic oncentrations CsA only marginally 
inhibits human neutrophil activation (Janco and English 
1983; Kharazmi et al. 1985; Wenzel-Seifert et al. 1991). 
Interestingly, FK-506 has recently been reported to be a 
very potent and effective inhibitor of A 23187-induced x- 
ocytosis in human neutrophils (Forrest et al. 1991). Addi- 
tionally, FK-506 partially inhibits interleukin-la release 
from human macrophages (Keicho et al. 1991) and po- 
tently inhibits mediator elease from basophils and mast 
cells (De Paulis et al. 1991a, b; Hultsch et al. 1991). All 
these findings prompted us to study in detail the effects 
of FK-506 on human neutrophil activation. We show here 
that FK-506 partially inhibits O~- production and exocy- 
tosis at supratherapeutic concentrations. 
Materials and methods 
Materials. FK-506 was kindly provided by Fujisawa Pharmaceutical 
Co., Ltd. (Osaka, Japan). Stock solutions of FK-506 (1 mM) were pre- 
pared in dimethyl sulfoxide and were stored in polypropylene tubes at 
-20°C under light protection for up to two months. Dilutions of 
FK-506 were made immediately prior to experiments. The final concen- 
tration of dimethyl sulfoxide in all experiments was adjusted to 0.1% 
(v/v). 12-(9-Anthroyloxy)-stearate (12-AS) was obtained from Molecu- 
lar Probes (Junction City, Ore., USA); 1,6-diphenylhexa-l,3,5-triene 
(DPH) was from EGA Chemic (Steinheim, FRG). Stock solutions of 
DPH (2 mM) were prepared in tetrahydrofurane and were kept at 25 °C. 
Stock solutions of 12-AS (1 raM) were prepared in 80% ethanol (v/v) 
and were kept at -20°C. Sources of other materials have been de- 
scribed elsewhere (Seifert et al. 1989a, b, 1992; Wenzel-Seifert and 
Seifert 1990; Wenzel-Seifert et al. 1991). 
Isolation of human neutrophils. Neutrophils were obtained from 12 
caucasian healthy volunteers ( ix males and six females) approximately 
2 h after a continental breakfast. Volunteers had taken no drugs for at 
least three weeks. The age of volunteers anged from 28-40 years; six 
of them were smokers. Isolation of neutrophils was performed as de- 
scribed (Seifert et al. 1989a). Cell preparations consisted of >95% 
viable neutrophils as revealed by trypan blue dye exclusion and Pap- 
penheim-stained smears. 
Assay for Oj production. 02 production was monitored at 550 nm by 
continuous measurement of ferricytochrome C reduction i hibitable by 
superoxide dismutase, using an Uvikon 810 dual beam spectrophotome- 
ter (Kontron, Eching, FRG) (Seifert et al. 1989a). Reaction mixtures 
(0.5 ml) contained 100 ~tM ferricytochrome C and a buffer consisting of 
(mM) 138NaC1, 6KCI, 1MgC12, 1CaC12, 5.5 glucose and 20 
Hepes/NaOH, pH 7.4. Neutrophils (1.0-2.0x 106 cells) or dibutyryl 
cAMP-differentiated HL-60 cells (2.5 × 10 6 cells) were suspended in the 
solution described above and were incubated for 5 min at 37 °C in the 
presence of FK-506 or solvent. 0 2 production was initiated by the ad- 
dition of stimuli. 
Assay for fl-glucuronidase and lysozyme release. Exocytosis was as- 
sessed as described (Seifert et al. 1989b; Wenzel-Seifert and Seifert 
1990; Wenzel-Seifert et al. 1991). In one set of experiments, neutrophils 
(4.0-5.0x106 cells) were incubated for 5min at 37°C in the buffer 
(0.5 ml) described above supplemented with cytochaiasin B (5 gg/ml) in 
the presence of FK-506 or solvent. Thereafter, stimuli were added to 
cells. In another set of experiments, neutrophils (4.0-5.0x106 ceils) 
were incubated for 25min at 20°C in the buffer (0.5ml) described 
above not supplemented with cytochalasin B, in the presence of FK-506 
or solvent. Thereafter, cells were incubated for additional 5 min at 37 °C 
in the presence of FK-506 or solvent plus cytochalasin B (5 gg/ml). Sub- 
sequently, stimuli were added to cells. Reactions were terminated after 
i0 min by rapid cooling to 4 °C. Reaction mixtures were centrifuged for 
10min at 1000xg. The determinations of the activities of fl- 
glucuronidase, lysozyme and lactate dehydrogenase of the supernatant 
fluids of reaction mixtures and of cell lysates were performed as de- 
scribed (Seifert et al. 1989b; Wenzel-Seifert and Seifert 1990; Wenzel- 
Seifert et al. 1991). Basal fl-glucuronidase, lysozyme and lactate 
dehydrogenase release amounted to less than 5°70 of cellular content 
(data not shown). 
Measurement of[Ca2+] i. [Caa+]i was determined using the fluorescent 
dye, Fura-2, as described (Wenzel-Seifert and Seifert 1990). Neutrophils 
were suspended at 5xl06cells/ml in a buffer consisting of (mM) 
138 NaC1, 6 KC1, 1 MgSO4, 1.1 CaCI2, 0.I EGTA, 1 NaaHPO4, 
5 NaHCO3, 5.5 glucose, 20 Hepes/NaOH, pH 7.4, supplemented with 
bovine serum albumin (0.1070, w/v). Cells were incubated for 1 h at 
37 °C in the presence of Fura-2 acetoxymethylester (4 IxM). Subsequent- 
ly, cells were diluted with the above buffer to a final concentration f 
0.5 × 10 6 cells/ml and were centrifuged for 10 min at 250x g at 20 °C. 
Cells were suspended at2.5 x 106 cells/ml in the above buffer and were 
kept at 20°C until measurement of [CaZ+] i. Fluorescence of 
neutrophils (2.5 x 106 cells in 2 ml) was determined at37 °C under con- 
stant stirring at 103 rpm using a Ratio II spectrofluorometer (Aminco, 
Silver Spring, Md., USA). Cells were incubated for 5 rain in the presence 
of FK-506 or solvent prior to the addition of stimuli. The excitation and 
emission wavelengths were 340 and 500 nm, respectively. 
Cell culture and membrane preparation. HL-60 ceils were cultured in 
suspension culture at 37 °C and were differentiated towards neutrophil- 
like cells upon incubation with dibutyryl cAMP (0.2 raM) for 48 h 
(Seifert et al. 1989a; Wenzel-Seifert and Seifert 1990). In some experi- 
ments, FK-506 or solvent were added to cultures 24 h prior to experi- 
ments. HL-60 membranes were prepared as described (Seifert and 
Schultz 1987). 
Steady-state and differential polarized phase fluorometry. DPH and 
12-AS were added from stock solutions to fluorometry buffer consisting 
of (mM) 100 mannitol, 10 Hepes/Tris, pH 7.4, and were stirred at 25 °C 
for 1 h and 5 min, respectively, to remove solvent. HL-60 membranes 
were suspended in these solutions to give final probe concentrations of 
1 ~xM (DPH) and 2 ~tM (12-AS); these mixtures were incubated in the 
dark for 30 min at 37 °C. Membranes were centrifuged for 20 min at 
48000×g at 4°C and were resuspended in fluorometry buffer at 
0.15 mg of protein/ml. Membranes were incubated for 10 min at 25 °C 
in the presence of FK-506 or solvent. Fluorescence measurements were 
performed at 25 °C in a SLM 4800 spectrofluorometer (SLM Instru- 
ments, Urbana, Ill. USA) equipped with a thermostated cuvette holder. 
Steady state-anisotropy was measured on the T formate with 360 nm 
(DPH) and 365 nm (12-AS) as excitation wavelengths. Emission light 
was filtered through KV-418 filters (Schott, Mainz, FRG). Fluorescence 
lifetimes were measured at 18 MHz by the phase modulation technique 
relative to a glycogen scatter solution (Spencer and Weber 1969). Differ- 
ential tangent was measured by differential polarized phase fluorometry 
at 18 MHz (Lakowicz et al. 1979). Rotational correlation time and limit- 
ing anisotropy were calculated from steady-state anisotropy, phase life- 
time, differential tangent and r 0, i.e. the anisotropy in the absence of 
motion (Lakowicz et aI. 1979). R 0 values of 0.390 (DPH) (Lakowicz et 
al. 1979) and 0.285 (12-AS) (Schachter and Shinitzky 1977) were used 
for calculations. 
fMet-Leu-[3H]Phe binding assay, fMet-Leu-[3H]Phe binding was per- 
formed as described (Wenzel-Seifert et al. 1991). Reaction mixtures 
(100 Ixl) contained 40 ~g of membrane protein from dibutyryl cAMP- 
differentiated HL-60 cells, bovine serum albumin (0.2%, w/v), 50 mM 
Tris/HC1, pH 7.3, 1 mM EDTA and 5 mM MgC12 in the presence of 
FK-506 or solvent. Incubations were conducted for 30 min at 25 °C and 
were initiated by the addition of 3 nM fMet-Leu-[3H]Phe. Reactions 
were terminated by rapid filtration technique. Radioactivity on dried fil- 
ters was determined in a liquid scintillation counter. Unspecific binding 
was determined in the presence of 10 ~xM fMet-Leu-Phe and amounted 
to less than 10070 of total binding. 
Measurement of GTPase activity. GTPase activity was measured as de- 
scribed (Seifert et al. 1992). Assay mixtures (:tO0 gl) contained mem- 
branes from HL-60 cells (7.0 Ixg of protein/tube), 0.5 ~tM [7-3~P]GTP ~ 
(0.1 ~Ci/tube), 0.5 mM MgC12, 0.1 mM EGTA, 0.1 mM ATP, I mM 
o 
adenosine 5'-[fl, ~-imido]-triphosphate, 5 mM creatine phosphate, 40 I~g .7. 
of creatine kinase, 1 mM dithiothreitol and 0.2% (w/v) bovine serum al- 
bumin in 50 mM triethanolamine/HC1, pH 7.4. Reaction mixtures were 
preincubated for 10min at 25°C with FK-506 or solvent. Thereafter, ._g 
fMet-Leu-Phe or H~O were added. After additional 10 min at 25 °C, 
reactions were initiated by the addition of [y-32P]GTP and were con- ~ 
ducted for 15 min. Low-affinity GTPase activity was determined in the 
presence of GTP (50 p~M) and amounted to < 5 % of total GTPase activ- 
ity. 
Miscellaneous. Protein was determined according to Lowry et al. 
(1951). The effects of FK-506 were statistically assessed using the 
Wilcoxon test. 
Results 
First, the effects of FK-506 on cell integrity were studied. 
FK-506 up to 1 gM did not cause damage of neutrophits 
and HL-60 cells as revealed by lactate dehydrogenase re- 
lease and trypan blue dye exclusion (data not shown). 
The effect of FK-506 at various concentrations on 
0 2 production induced by fMet-Leu-Phe (50nM) is 
shown in Fig. 1. FK-506 above 100 nM inhibited the abso- 
lute amount and maximum rate of O~- production by up 
to 35%. At lower concentrations, FK-506 was ineffective. 
The effects of FK-506 (1 gM) on 0 2 production and 
on rises in [Ca2+l i nduced by various stimuli were stud- 
ied. fMet-Leu-Phe activated 02 production with an 
EC50 of 45 nM and a maximum at 300 nM (Fig. 2). 
FK-506 reduced O~- production by about 30% at all 
fMet-Leu-Phe concentrations employed, and it did not 
substantially increase the ECs0. fMet-Leu-Phe increased 
[Ca2+li with an EC50 of 0.4nM and a maximum at 
30 nM (see Fig. 2); FK-506 was without effect on rises in 
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Fig. 2. Effect of FK-506 on concentration-response functions to fMet- 
Leu-Phe-induced O 2 production and rises in [Ca2+] i in human 
neutrophils. FK-506 (1 IxM) (0)  or solvent (control) (©) were added to 
reaction mixtures 5 min prior to fMet-Leu-Phe at various concentra- 
tions. Open squares how that fMet-Leu-Phe at the indicated concen- 
trations did not activate O~- production or increase [Ca2+] i. Data 
shown are the means+SEM of assay triplicates of four experiments car- 
ried out with neutrophils from different donors. Comparison of the ef- 
fect of FK-506 versus control, *P<0.05 
[Ca2+]i. PAF activated 02 production and increased 
[Ca2+]i with ECs0 values of 300nM and 5 nM, respec- 
tively (Fig. 3). Similar to fMet-Leu-Phe, FK-506 inhibited 
PAF-induced 0 2 production by about 30°70, but it did 
not affect rises in [Ca2+] i. FK-506 did not inhibit 0 2 
production induced by C5a (1 and 10 nM), leukotriene 
B 4 (1 BM), A23187 (10 gM) and 4p-phorbol 12-myristate 
13-acetate (PMA) (10, 30 and 100 ng/ml) and increases in 
[ Ca2+ ]i induced by CSa (0.01- 3 nM) and leukotriene B4 
(0.3 - 100 nM) (data not shown). FK-506 by itself did not 
induce a rise in [Ca2+] i and did not activate O~- produc- 
tion (data not shown). 
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Fig. 1. Concentration-response function o FK-506 of fMet-Leu-Phe-in- 
duced O~- production in human neutrophils. The effect of FK-506 on 
the absolute amount and maximum rate of O~ production induced by 
fMet-Leu-Phe (50 nM) was studied. FK-506 or solvent (control) were 
added to reaction mixtures 5 min prior to fMet-Leu-Phe. Data shown 
are the means _+ SEM of assay triplicates of five experiments carried out 
with nentrophils from different donors. Comparison of the effect of 
FK-506 versus control, *P <0.05 
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Fig. 3. Effect of FK-506 on concentration-response functions to PAF-in- 
duced O~- production and rises in [Ca2+]i in human neutrophils. 
FK-506 (1 gM) ( I )  or solvent (control) ([5) were added to reaction mix- 
tures 5 min prior to PAF at various concentrations. Open circles show 
that PAF at the indicated concentrations did not activate O~- produc- 
tion or increase [Ca2+] i. Data shown are the means+_SEM of assay 
triplicates of five experiments carried out with neutrophils from differ- 
ent donors. Comparison of the effect of FK-506 versus control, 
*P <0.05 
10 
Table 1. Effect of FK-506 on fl-glucuronidase and lysozyme release in human neutrophils 
Addition Enzyme release (% of cellular content) 
Preincubation 
25 min (20 °C) + 5 min (37 °C) 5 min (37 °C) 
fl-Glucuronidase Lysozyme fl-Glucuronidase Lysozyme 
A23187 (5 gM) + solvent 
A23187 (5 gM)+FK-506 
fMet-Leu-Phe (30 nM)+ solvent 
fMet-Leu-Phe (30 nM)+ FK-506 
PAF (1 gM) + solvent 
PAF (1 gM) + FK-506 
31 _+2 47_+4 24_+2 47_+5 
19+1 c 31-+4 b 15-+1 c 36_+5 b 
10-+1 19-+2 12-+2 13-+1 
10___1 a 19_+2 a 11-+1 a 13_+2 a
17-+1 17_+3 18_+2 18_+2 
14_+2 a 16_+3 a 15_+1 a 15_+1 a
Neutrophils were preincubated with FK-506 (1 gM) or solvent (control) under various conditions. Release of fl-glucuronidase and lysozyme induced 
by various timuli was assessed. Data shown are the means +SEM of assay triplicates of four experiments carried out with neutrophils from different 
donors 
Comparison of the effect of FK-506 versus control 
a Not significant 
b P<0.05 
c P<0.01 
Table 2. Effect of FK-506 on Of  production in dibutyryl cAMP-dif- 
ferentiated HL-60 cells 
Addition O 2 production (nmol/106 cells) 
Preincubation 
5 min (37°C) 24h (37°C) 
Solvent 2.1 _+ 0.2 2.0 + 0.2 
FK-506 1.5 + 0.2 b 2.2 + 0.2 a 
In one set of experiments, HL-60 cells were harvested and preincubated 
for 5 min with FK-506 (1 IxM) or solvent (control) prior to the addition 
of fMet-Leu-Phe (1~tM). In another set of experiments, FK-506 (1 gM) 
or solvent (control) were added to cell cultures 24 h prior to ex- 
periments. Subsequently, cells were harvested and O~- production i - 
duced by fMet-Leu-Phe (1 p.M) was assessed. Data shown are the 
means +SEM of assay triplicates of four experiments with different 
preparations of ttL-60 cells 
Comparison of the effect of FK-506 versus control 
a Not significant 
b P< 0.05 
The effects of FK-506 on exocytosis are shown in Ta- 
ble1. FK-506 (l~tM) inhibited A23187-induced fl- 
glucuronidase and lysozyme release by 30-40%,  
regardless of whether cells were incubated with the drug 
for 25 min at 20 °C plus 5 min at 37 °C or only for 5 min 
at 37°C. FK-506 did not inhibit fMet-Leu-Phe- and 
PAFF-induced exocytosis. FK-506 per se did not activate 
exocytosis (data not shown). 
Modulation by FK-506 of Of  production in dibuty- 
ryl cAMP-differentiated HL-60 cells is shown in Table 2. 
After preincubation for 5 rain at 37 °C FK-506 inhibited 
fMet-Leu-Phe-induced O~- production by about 20%. 
By comparison, fMet-Leu-Phe-induced O2 production 
was not altered in cells preincubated with FK-506 for 24 h 
at 37 °C. 
The effect of FK-506 on binding of fMet- 
Leu-[3H]Phe (3 nM) to formyl peptide receptors in mem- 
branes from dibutyryl cAMP-differentiated HL-60 cells 
was investigated. Agonist-binding in control membranes 
was 568+27 fmol/mg protein. FK-506 (1 gM) did not 
alter agonist-binding to formyl peptide receptors 
(569_+ 24 fmol/mg protein). 
Modulation by FK-506 of high-affinity GTPase activ- 
ity in membranes from dibutyryl cAMP-differentiated 
HL-60 cells was studied. Basal GTP hydrolysis was 
17.1 ___ 1.5 pmol Pi/mg protein/rain, fMet-Leu-Phe 
(0.3 gM) stimulated GTP hydrolysis by 80%. FK-506 
(1 ~tM) showed no effect on basal and fMet- 
Leu-Phe-stimulated GTP hydrolysis (data not shown). 
Finally, the effect of FK-506 on physical state of 
HL-60 membranes was studied. Steady-state anisotropy 
in control membranes was 0.2109_+0.0033 with DPH as 
probe. Phase lifetime of DPH was 9.47 +0.07 ns. Limiting 
anisotropy was 0.180_+0.002 and rotational correlation 
time was 1.62+0.11 ns. FK-506 (1 ~tM) had no effect on 
these parameters (data not shown). Steady-state anisotro- 
py and phase lifetime of 12-AS in control membranes 
were 0.0849_+0.0015 and ll.12_+0.10ns, respectively; 
FK-506 (1 gM) showed no effect on these parameters. 
FK-506 did not change limiting anisotropy and rotational 
correlation time of 12-AS in HL-60 membranes (data not 
shown). 
Discussion 
We found that FK-506 partially inhibited fMet-Leu-Phe- 
and PAF-induced 02  production and A23187-induced 
exocytosis in human neutrophils at a supratherapeutic 
concentration (1 gM) (see Figs. 2 and 3 and Table i) 
(Starzl et al. 1989). Additionally, FK-506 (1 gM) slightly 
inhibited fMet-Leu-Phe-induced O;  production in dif- 
ferentiated HL-60 cells (see Table2). These findings 
prompted us to study the effects of FK-506 at therapeutic 
concentrations on fMet-Leu-Phe-induced 02  produc- 
tion in human neutrophils as fMet-Leu-Phe is assumed to 
play a key role in neutrophil activation in bacterial infec- 
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tions (see Fig. 1) (Rossi 1986; Sandborg and Smolen 1988; 
Seifert and Schultz 1991). However, at therapeutic con- 
centrations (0.1- 1 nM) (Starzl et al. 1989), FK-506 did 
not inhibit O~- production induced by fMet-Leu-Phe 
(see Fig. 1). Additionally, FK-506 was without effect on 
O~- formation induced by leukotriene B4 and CSa, two 
other physiologically relevant chemoattractants (Rossi 
1986; Sandborg and Smolen 1988; Seifert and Schultz 
1991). Furthermore, FK-506 did not at all affect exocy- 
tosis induced by fMet-Leu-Phe and PAF (see Table 1). 
These data suggest hat the only partial inhibition of 
neutrophil activation by FK-506 at supratherapeutic con- 
centrations i without clinical relevance and that FK-506 
at therapeutic oncentrations i  unlikely to impair the 
non-specific defense system substantially. 
The effects of FK-506 on neutrophil activation 
showed some similarities with the corresponding effects 
of CsA. The effectiveness of CsA and FK-506 (1 gM 
each) to inhibit fMet-Leu-Phe-induced O~- production is 
similar (see Figs. 1 and 2) (Wenzel-Seifert et al. 1991). 
Like CsA, FK-506 did not inhibit fMet-Leu-Phe- and 
PAF-induced exocytosis and rises in [Ca2+]i (see Figs. 2 
and 3 and Table 1) (Wenzel-Seifert e al. 1991). Similar to 
CsA, FK-506 did not interfere with agonist-binding to 
formyl peptide receptors (Wenzel-Seifert et al. 1991). 
However, unlike CsA, FK-506 partially inhibited PAF-in- 
duced O~- production (see Fig. 3) (Wenzel-Seifert et al. 
1991). These data suggest hat FK-506 and CsA inhibit 
neutrophil activation through related but not identical 
mechanisms. 
FKBP is ubiquitously distributed in eukaryotic ells 
(Siekierka et al. 1989). In human lymphocytes, the poten- 
cy of FK-506 in functional assays (ICs0 approximately 
0.1 nM) is in accordance with the affinity of FK-506 to 
FKBP (KD) of 0.4-0.8 nM) (Sigal and Dumont 1992; 
Siekierka et al. 1989). These data suggest that the 
FK-506-FKBP complex mediates the immunosuppressive 
effects of the drug in these cells. In addition, FK-506 in- 
hibits activation of mast cells and basophils with ICs0 
values of 1 -5  nM (De Paulis et al. 1991a, b; Hultsch et 
al. 1991). By comparison, FK-506 at these concentrations 
was without effect on fMet-Leu-Phe-induced O~- pro- 
duction, and FK-506 (1 gM) showed no or only relatively 
small inhibitory effects on various neutrophil activation 
parameters ( ee Figs. 1 - 3 and Tables 1 and 2). These data 
suggest that the inhibitory effects of FK-506 on 
neutrophil activation are not mediated by the FK-506- 
FKBP complex. It cannot, however, be excluded that 
FK-506 penetrates the neutrophil plasma membrane only 
poorly, i.e. the drug has to be present at very high extra- 
cellular concentrations to reach sufficient concentrations 
in the cytosol for interaction with FKBP. 
Several other possibilities have to be discussed to ex- 
plain the inhibitory effects of FK-506 on human neutro- 
phil activation. First, the failure of FK-506 to inhibit 
agonist-binding to formyl peptide receptors uggests that 
it does not act as formyl peptide receptor antagonist. Sec- 
ond, the lack of effect of FK-506 on high-affinity GTPase 
in HL-60 membranes indicates that the drug does not in- 
terfere with G-proteins. Third, FK-506 did not inhibit 
PMA-induced O~- production suggesting that it does not 
act as inhibitor of protein kinase C. Fourth, the lack of 
effect of FK-506 on 02 production induced by various 
stimuli implies that it does not interfere with a compo- 
nent of NADPH oxidase, the 02-generating enzyme sys- 
tem (Rossi 1986; Seifert and Schultz 1991). Similarly, the 
failure of FK-506 to inhibit exocytosis by various stimuli 
implies that it does not interfere with secretory mecha- 
nisms in an unspecific manner (see Table 1). Additionally, 
the lack of effect of FK-506 on fMet-Leu-Phe- and PAF- 
induced rises in [Ca2+]i ndicates that the drug does not 
interfere with Ca 2+ mobilization and/or Ca 2+ influx 
from the extracellular space (see Figs. 2 and 3). Further- 
more, we did not observe toxic effects of FK-506 on 
human neutrophils. Finally, the inhibitory effects of 
FK-506 were evident after short-term preincubation of 
cells but not after long-term treatment (see Figs. 1 - 3 and 
Tables 1 and 2). Thus, FK-506 apparently does not act via 
inhibition of gene transcription or protein synthesis. In- 
terestingly, inhibitory effects of FK-506 on basophil and 
mast cell activation are also evident after short-term 
preincubation (De Paulis et al. 1991 a,b; Hultsch et al. 
1991). 
FK-506 is a very lipophilic drug (Kino et al. 1987). 
This fact and the supratherapeutic concentrations of 
FK-506 required to partially inhibit neutrophil activation 
(see Fig. 1) (Starzl et al. 1989) raise the question of wheth- 
er the drug acts via alteration of physical membrane state. 
A widely employed technique for the study of physical 
membrane state is steady-state polarization and differen- 
tial polarized phase fluorometry with DPH and 12-AS as 
probes. Absolute steady-state anisotropy of DPH in dibu- 
tyryl cAMP-differentiated HL-60 membranes was similar 
to the one in membranes from dimethyl sulfoxide-dif- 
ferentiated HL-60 cells, human neutrophils, lymphocytes 
and erythrocytes (Shinitzky and Inbar 1974; Ip and Coo- 
per 1980; Giraud et al. 1991; Yuli et al. 1982). Limiting 
anisotropy reflects lipid packing order in the membrane 
restricting the probes' rotational motion, i.e. it is a static 
measure; rotational correlation time reflects mobility of 
the probe in the lipid environment, i.e. it is a dynamic 
measure (Lakowicz et al. 1979). The lack of effect of 
FK-506 on limiting anisotropy and rotational correlation 
time clearly argues against alterations in physical mem- 
brane state accounting for its partial inhibitory effects on 
neutrophil activation. Taken together, the mechanism of 
action of FK-506 in human neutrophils i still unknown. 
There are some similarities and dissimilarities be- 
tween the results obtained by us und by Forrest et al. 
(1991). In agreement with our data are their findings that 
FK-506 and CsA do not inhibit fMet-Leu-Phe-induced 
exocytosis ( ee Table 1) (Wenzel-Seifert e al. 1991). How- 
ever, Forrest et al. (1991) reported that FK-506, after 
preincubation for 25 min at room temperature, inhibited 
exocytosis induced by A23187 at a maximally effective 
concentration (1gM) in human neutrophils with an ICs0 
of about 1 nM and a maximum at 10 nM. In our hands, 
A23187 was maximally effective at 5gM, whereas 
A23187 at i gM induced the release of only about 5% of 
the cellular content of fl-glucuronidase r lease, i.e. this 
stimulation was too small for reliable quantitative assess- 
ment of the inhibitory effect of FK-506 (data not shown). 
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Differences in the maximally effective concentrations of 
A23187 for stimulation of exocytosis among various 
groups have been reported before (Kang et al. 1985; 
Becker et al. 1985; Naccache t al. 1985). In contrast to 
Forrest et al. (1991), we found that FK-506 as high as 
1 ~tM showed only relatively small inhibitory effects on 
A23 187-induced exocytosis, regardless of whether cells 
were preincubated with the drug for 25 min at 20 °C plus 
5 rain at 37 °C or only for 5 min at 37 °C (see Table 1). 
Basically, the methods applied by us and by Forrest et al. 
(1991) (see Materials and methods) were similar. It is pos- 
sible that differences in responsiveness to FK-506 of 
neutrophils in both studies existed. Interestingly, Kahan 
et al. (1991) reported on substantial variation in respon- 
siveness to FK-506 among lymphocytes from different 
donors. In addition, it is known that regulation of 02 
production may depend on several conditions such as sex, 
age, active and passive smoking, feeding state and meth- 
od of cell isolation (Seifert and Schultz 1991; Lipschitz et 
al. 1991; Anderson et al. 1991; Uhlinger et al. 1991). With 
regard to the donors studied by us, however, FK-506 
showed very consistent effects (see Figs. 1- 3 and Table 
1). Specifically, we did not observe that neutrophils of 
some donors were highly sensitive to inhibition by 
FK-506, whereas cells from other donors were insensitive. 
Unfortunately, Forrest et al. (1991) did not provide suffi- 
cient information on the above-mentioned factors in their 
volunteers. Regardless of the reason for the differences 
between our results and those of Forrest et al. (1991) 
should it be kept in mind that A23 187, unlike fMet- 
Leu-Phe, C5a, PAF and leukotriene B4, is not a physio- 
logically relevant stimulus (Rossi 1986; Sandborg and 
Smolen 1988; Seifert and Schultz 1991). 
In conclusion, we have shown that FK-506 at 
therapeutic oncentrations does not inhibit human 
neutrophil activation. At supratherapeutic concentra- 
tions FK-506 partially inhibits neutrophil activation 
through a mechanism which is rapid in onset and does 
not involve inhibition of agonist binding to formyl pep- 
tide receptors, interference with G-proteins or protein 
kinase C, reduction of rises in  [Ca2+]i or changes in 
physical membrane state. 
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